Skip to main content
Top
Published in: Rheumatology International 7/2021

01-07-2021 | Rheumatoid Arthritis | Observational Research

Immunoglobulin deficiencies in treated patients suffering from rheumatoid arthritis

Authors: Sara Kaestner, Hans-Juergen Wolff, Rolf Braeuer, Peter Kaestner

Published in: Rheumatology International | Issue 7/2021

Login to get access

Abstract

Immunoglobulins and antibodies to immunoglobulins (autoimmunoglobulins) have been identified to be implicated in the pathogenesis of rheumatoid arthritis (RA). Immunoglobulin deficiencies have been suggested to account for the increased risk of infections in RA patients. This study was carried out to determine the prevalence of immunoglobulin deficiencies in patients with RA and the identification of putative contributing factors. Immunoglobulin levels in blood samples of patients with rheumatoid arthritis were evaluated by an immunonephelometric assay. Demographic and disease related data (including age, sex, smoking habits, disease duration and activity, inflammatory markers) were assessed, and associations were identified by regression analysis. 539 patients were enrolled between 2011 and 2013. The most common immunoglobulin (Ig) deficiencies were those of IgM (24.5%) and IgG (19.9%). Most frequent deficiencies of subclasses were observed for IgG1 (42.3%), followed by IgG4 (10.4%), IgG2 (7.2%), and IgG3 (5.4%). Regression analyses revealed that deficiencies of IgM, IgG, IgG1, and IgG2 were more prevalent in older patients. In addition, smoking was associated with IgG2 deficiency, and IgA deficiency was associated with female sex. Occurrence of infections was significantly increased in patients with IgG, IgG2, and IgG4 deficiencies. RA patients displayed high rates of IgG and IgM deficiencies. In consequence, the assessment of immunoglobulin status should precede the application of immune modulating drugs to prevent a potential risk of infectious diseases. Prospective studies are needed to investigate the influence of immune modulating drugs on IgG and IgG subclass levels.
Appendix
Available only for authorised users
Literature
2.
go back to reference Classen M, Diehl V, Kochsiek K, Hallek M, Böhm M, Schmiegel W (2009) Innere Medizin. Elsevier Classen M, Diehl V, Kochsiek K, Hallek M, Böhm M, Schmiegel W (2009) Innere Medizin. Elsevier
3.
go back to reference Aho K, Heliovaara M, Knekt P, Reunanen A, Aromaa A, Leino A, Kurki P, Heikkila R, Palosuo T (1997) Serum immunoglobulins and the risk of rheumatoid arthritis. Ann Rheum Dis 56(6):351–356CrossRef Aho K, Heliovaara M, Knekt P, Reunanen A, Aromaa A, Leino A, Kurki P, Heikkila R, Palosuo T (1997) Serum immunoglobulins and the risk of rheumatoid arthritis. Ann Rheum Dis 56(6):351–356CrossRef
7.
go back to reference Leddy JP, Deitchman J, Bakemeier RF (1970) IgG subclasses measurement of radioimmunoassay in normal and hypogammaglobulinaemic sera. Arthritis Rheum 13:331–332 Leddy JP, Deitchman J, Bakemeier RF (1970) IgG subclasses measurement of radioimmunoassay in normal and hypogammaglobulinaemic sera. Arthritis Rheum 13:331–332
8.
go back to reference Shakib F, Stanworth DR, Drew R, Catty D (1975) A quantitative study of the distribution of IgG sub-classes in a group of normal human sera. J Immunol Methods 8(1–2):17–28CrossRef Shakib F, Stanworth DR, Drew R, Catty D (1975) A quantitative study of the distribution of IgG sub-classes in a group of normal human sera. J Immunol Methods 8(1–2):17–28CrossRef
9.
go back to reference van der Giessen M, Rossouw E, van Veen TA, van Loghem E, Zegers BJ, Sander PC (1975) Quantification of IgG subclasses in sera of normal adults and healthy children between 4 and 12 years of age. Clin Exp Immunol 21(3):501–509PubMedPubMedCentral van der Giessen M, Rossouw E, van Veen TA, van Loghem E, Zegers BJ, Sander PC (1975) Quantification of IgG subclasses in sera of normal adults and healthy children between 4 and 12 years of age. Clin Exp Immunol 21(3):501–509PubMedPubMedCentral
10.
go back to reference Oxelius VA (1978) Crossed immunoelectrophoresis and electroimmunoassay of human IgG subclasses. Acta pathologica et microbiologica Scandinavica Section C, Immunology 86C(3):109–116PubMed Oxelius VA (1978) Crossed immunoelectrophoresis and electroimmunoassay of human IgG subclasses. Acta pathologica et microbiologica Scandinavica Section C, Immunology 86C(3):109–116PubMed
11.
go back to reference French MA, Harrison G (1984) Serum IgG subclass concentrations in healthy adults: a study using monoclonal antisera. Clin Exp Immunol 56(2):473–475PubMedPubMedCentral French MA, Harrison G (1984) Serum IgG subclass concentrations in healthy adults: a study using monoclonal antisera. Clin Exp Immunol 56(2):473–475PubMedPubMedCentral
12.
go back to reference Madassery JV, Kwon OH, Lee SY, Nahm MH (1988) IgG2 subclass deficiency: IgG subclass assays and IgG2 concentrations among 8015 blood donors. Clin Chem 34(7):1407–1413CrossRef Madassery JV, Kwon OH, Lee SY, Nahm MH (1988) IgG2 subclass deficiency: IgG subclass assays and IgG2 concentrations among 8015 blood donors. Clin Chem 34(7):1407–1413CrossRef
13.
go back to reference Schauer U, Stemberg F, Rieger CH, Borte M, Schubert S, Riedel F, Herz U, Renz H, Wick M, Carr-Smith HD, Bradwell AR, Herzog W (2003) IgG subclass concentrations in certified reference material 470 and reference values for children and adults determined with the binding site reagents. Clin Chem 49(11):1924–1929CrossRef Schauer U, Stemberg F, Rieger CH, Borte M, Schubert S, Riedel F, Herz U, Renz H, Wick M, Carr-Smith HD, Bradwell AR, Herzog W (2003) IgG subclass concentrations in certified reference material 470 and reference values for children and adults determined with the binding site reagents. Clin Chem 49(11):1924–1929CrossRef
14.
go back to reference Liu F, Wang Q, Qiu YR, Li MM (2003) Analysis of the relation between serum immunoglobulin and auto-antibody levels in patients with rheumatoid. Acad J First Med Coll PLA 23(5):472–473 Liu F, Wang Q, Qiu YR, Li MM (2003) Analysis of the relation between serum immunoglobulin and auto-antibody levels in patients with rheumatoid. Acad J First Med Coll PLA 23(5):472–473
16.
go back to reference Neumann C, Proft F, Hammitzsch A, Gruenke M, Schulze-Koops H (2013) Hypogammaglobulinemia is a frequent finding in patients under immunosuppressive therapy but does not correlate with susceptibility to infections. Ann Rheum Dis 72(3):338 Neumann C, Proft F, Hammitzsch A, Gruenke M, Schulze-Koops H (2013) Hypogammaglobulinemia is a frequent finding in patients under immunosuppressive therapy but does not correlate with susceptibility to infections. Ann Rheum Dis 72(3):338
17.
go back to reference Deutsche Gesellschaft für Rheumatologie (2012) German guidelines for the sequential medical treatment of rheumatoid arthritis 2012: adapted EULAR recommendations and update of a treatment algorithm. AWMF-Register Nr 060/004 Deutsche Gesellschaft für Rheumatologie (2012) German guidelines for the sequential medical treatment of rheumatoid arthritis 2012: adapted EULAR recommendations and update of a treatment algorithm. AWMF-Register Nr 060/004
18.
go back to reference Bukhari M, Wiles N, Lunt M, Harrison B, Scott D, Symmons D, Silman A (2003) Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthr Rheumatol 48(1):46–53CrossRef Bukhari M, Wiles N, Lunt M, Harrison B, Scott D, Symmons D, Silman A (2003) Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthr Rheumatol 48(1):46–53CrossRef
19.
go back to reference Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581. https://doi.org/10.1002/art.27584CrossRef Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581. https://​doi.​org/​10.​1002/​art.​27584CrossRef
20.
go back to reference Bull B, Caswell M, Ernst E, Jou J, Kallner A, Koepke J, Lewis S, Lowe G, Rampling M, Stuart J (1993) ICSH recommendations for measurement of erythrocyte sedimentation-rate. J Clin Pathol 46(3):198–203CrossRef Bull B, Caswell M, Ernst E, Jou J, Kallner A, Koepke J, Lewis S, Lowe G, Rampling M, Stuart J (1993) ICSH recommendations for measurement of erythrocyte sedimentation-rate. J Clin Pathol 46(3):198–203CrossRef
21.
go back to reference Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and rheumatism 38(1):44–48CrossRef Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and rheumatism 38(1):44–48CrossRef
22.
go back to reference Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL (2009) Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68(6):954–960. https://doi.org/10.1136/ard.2007.084459CrossRefPubMed Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL (2009) Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68(6):954–960. https://​doi.​org/​10.​1136/​ard.​2007.​084459CrossRefPubMed
23.
go back to reference Barden J, Mullinax F, Waller M (1967) Immunoglobulin levels in rheumatoid arthritis: comparison with rheumatoid factor titers, clinical stage and disease duration. Arthritis Rheum 10(3):228–234CrossRef Barden J, Mullinax F, Waller M (1967) Immunoglobulin levels in rheumatoid arthritis: comparison with rheumatoid factor titers, clinical stage and disease duration. Arthritis Rheum 10(3):228–234CrossRef
24.
go back to reference Claman H, Merrill D (1966) Serum immunoglobulins in rheumatoid arthritis. J Lab Clin Med 67(5):850–854PubMed Claman H, Merrill D (1966) Serum immunoglobulins in rheumatoid arthritis. J Lab Clin Med 67(5):850–854PubMed
25.
go back to reference Marcolongo R, Carcassi A, Frullini F, Bianco G, Bravi A (1967) Levels of serum immunoglobulins in patients with rheumatoid arthritis. Ann Rheum Dis 26(5):412–418CrossRef Marcolongo R, Carcassi A, Frullini F, Bianco G, Bravi A (1967) Levels of serum immunoglobulins in patients with rheumatoid arthritis. Ann Rheum Dis 26(5):412–418CrossRef
26.
go back to reference Veys E, Claessens H (1968) Serum levels of IgG, IgM, and IgA in rheumatoid arthritis. Ann Rheum Dis 27(5):431CrossRef Veys E, Claessens H (1968) Serum levels of IgG, IgM, and IgA in rheumatoid arthritis. Ann Rheum Dis 27(5):431CrossRef
27.
go back to reference Lock R, Unsworth D (2003) Immunoglobulins and immunoglobulin subclasses in the elderly. Ann Clin Biochem 40(2):143–148CrossRef Lock R, Unsworth D (2003) Immunoglobulins and immunoglobulin subclasses in the elderly. Ann Clin Biochem 40(2):143–148CrossRef
28.
go back to reference Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Meijide L, Fernandez-Merino C, Vidal C (2008) Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol 151(1):42–50CrossRef Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Meijide L, Fernandez-Merino C, Vidal C (2008) Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol 151(1):42–50CrossRef
29.
go back to reference Roseman C, Truedsson L, Kapetanovic MC (2012) The effect of smoking and alcohol consumption on markers of systemic inflammation, immunoglobulin levels and immune response following pneumococcal vaccination in patients with arthritis. Arthritis Res Ther 14(4):R170CrossRef Roseman C, Truedsson L, Kapetanovic MC (2012) The effect of smoking and alcohol consumption on markers of systemic inflammation, immunoglobulin levels and immune response following pneumococcal vaccination in patients with arthritis. Arthritis Res Ther 14(4):R170CrossRef
30.
go back to reference Schur PH, Borel H, Gelfand EW, Alper CA, Rosen FS (1970) Selective gamma-G globulin deficiencies in patients with recurrent pyogenic infections. N Engl J Med 283(12):631–634CrossRef Schur PH, Borel H, Gelfand EW, Alper CA, Rosen FS (1970) Selective gamma-G globulin deficiencies in patients with recurrent pyogenic infections. N Engl J Med 283(12):631–634CrossRef
31.
go back to reference Schmidt R, Baumann U (2011) Humorale Immundefekte. Primäre und Sekundäre Imundefekte. Uni-Med, 3. neubearb. Auflage 2011. . Schmidt R, Baumann U (2011) Humorale Immundefekte. Primäre und Sekundäre Imundefekte. Uni-Med, 3. neubearb. Auflage 2011. .
32.
go back to reference Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo R, Godeau B, Guillevin L (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthr Rheumatol 62(9):2625–2632CrossRef Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo R, Godeau B, Guillevin L (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthr Rheumatol 62(9):2625–2632CrossRef
33.
go back to reference Shaffu S, Royle J, Neame R (2013) AB0332 Rituximab & immunoglobulin level monitoring in rheumatoid arthritis–a clinical audit. Ann Rheum Dis 72(Suppl 3):A888–A889CrossRef Shaffu S, Royle J, Neame R (2013) AB0332 Rituximab & immunoglobulin level monitoring in rheumatoid arthritis–a clinical audit. Ann Rheum Dis 72(Suppl 3):A888–A889CrossRef
34.
go back to reference Van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37(3):558–567CrossRef Van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37(3):558–567CrossRef
35.
go back to reference Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg J-E, Isaacs J, Kvien TK (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70(6):909–920CrossRef Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg J-E, Isaacs J, Kvien TK (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70(6):909–920CrossRef
36.
go back to reference De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G (2012) Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology 51(5):833–840CrossRef De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G (2012) Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology 51(5):833–840CrossRef
Metadata
Title
Immunoglobulin deficiencies in treated patients suffering from rheumatoid arthritis
Authors
Sara Kaestner
Hans-Juergen Wolff
Rolf Braeuer
Peter Kaestner
Publication date
01-07-2021
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 7/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-021-04871-x

Other articles of this Issue 7/2021

Rheumatology International 7/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.